Longeveron Inc. (LGVN): Gross Profit
$803.0K
Year ended 2025-12-31
$828.0K
Trailing 12 months to 2026-06-30
+17.3%
3-year compound annual growth
-15.2%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $803.0K | -57.4% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $1.88M | +752.5% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $221.0K | -55.5% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $497.0K | -15.8% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $590.0K | -67.7% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $1.83M | n/a | 2022-03-11, From 2020-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Longeveron Inc. (LGVN) | 2025-12-31 | $803.0K | -57.4% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $248.7K | -32.3% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $619.0K | -15.6% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $452.9K | +32.0% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$2.08M | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $734.4K | n/a |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $223.8K | +0.4% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $940.0K | n/a |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $632.9K | -40.0% |
Compare LGVN, SXTC, IGC, BSPK side by side · Screen every company in Pharmaceutical Preparations ↗